A 'surprising' Phase III knocks back AstraZeneca, Amgen's blockbuster asthma ambitions
Two months have brought two very different results for Amgen, AstraZeneca and their blockbuster-potential asthma drug.
The companies announced Tuesday that the drug — a once …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.